The World's Most (and Least) Powerful Passports in 2025
LONDON, Jan. 8, 2025 /PRNewswire/ -- Singapore reclaims its crown as the most powerful passport in the world with visa-free access to 195 out of 227 destinations worldwide, leaving Japan as runner-up with a score of 193, according to the 2025 Henley...
U.S. FDA Granted Priority Review to Dizal's Sunvozertinib New Drug Application
If approved, Sunvozertinib as a single oral drug would offer a convenient and safe treatment option with superior efficacy for NSCLC patients with EGFR exon20ins Sunvozertinib's NDA was submitted based on the multinational pivotal WU-KONG1 Part B...
CHINA NATURAL RESOURCES GRANTED SECOND 180-DAY PERIOD BY NASDAQ TO REGAIN COMPLIANCE WITH MINIMUM BID PRICE RULE
HONG KONG, Jan. 6, 2025 /PRNewswire/ -- China Natural Resources Inc. (NASDAQ: CHNR) (the "Company") today announced that on January 3, 2025, the Company has been granted an additional 180-day period from Nasdaq's Listing Qualifications Department,...
Thailand BOI Approves 10.5 Billion Baht Investment by Foxsemicon Integrated Technology's Subsidiary to Make High-Precision Machinery Parts and Equipment for Semiconductor Sector
BANGKOK, Dec. 11, 2024 /PRNewswire/ -- The Thailand Board of Investment (BOI) today announced it has granted investment privileges to a 10.5 billion baht (ca. US$ 306 million) investment by UNIQUE Integrated Technology Co., Ltd., a subsidiary of...
FDA Granted Orphan Drug Designation of LBL-024, An Anti-PD-L1/4-1BB Bispecific Antibody Developed by Leads Biolabs, for Treatment of Neuroendocrine Cancer
NANJING, China, Nov. 22, 2024 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") announced that LBL-024, an anti-PD-L1/4-1BB bispecific antibody independently developed by the company with global...
InxMed FAK Inhibitor Ifebemtinib Received Breakthrough Therapy Designation by China National Medical Products Administration for First-Line Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation
NANJING, China, Nov. 21, 2024 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company developing innovative therapies against cancer treatment resistance and metastasis, announced that China National Medical Products Administration...